Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric... Gastric Cancer (2011) 14:50–55 DOI 10.1007/s10120-011-0007-7 O R I G IN AL ARTI CL E Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis • • Francesco Montagnani Gina Turrisi • • Claudio Marinozzi Camillo Aliberti Giammaria Fiorentini Received: 10 August 2010 / Accepted: 26 September 2010 / Published online: 23 February 2011 The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2011 Abstract thromboembolic events (OR = 0.42, p \ 0.01), but it was Background Cisplatin has been largely used in the treat- also associated with increased neurotoxicity (OR = 6.91, ment of advanced, unresectable gastric cancer, mainly in p \ 0.01). combinations with fluoropyrimidines and anthracyclines. Conclusions Our results support the existence of a small Oxaliplatin has been shown to be at least as effective as but significant survival benefit of oxaliplatin over cisplatin. cisplatin for this disease, but with less toxicity and a better Oxaliplatin is associated with less toxicity and better tol- tolerability profile, especially for older patients. We per- erability, especially in older patients and when used in two- formed a systematic review of the literature to address and drug, bi-weekly regimens. quantify http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Gastric Cancer Springer Journals

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis

Loading next page...
 
/lp/springer-journals/effectiveness-and-safety-of-oxaliplatin-compared-to-cisplatin-for-KfmgNnuW8t

References (25)

Publisher
Springer Journals
Copyright
Copyright © 2011 by The International Gastric Cancer Association and The Japanese Gastric Cancer Association
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Pathology; Radiotherapy; Gastroenterology
ISSN
1436-3291
eISSN
1436-3305
DOI
10.1007/s10120-011-0007-7
pmid
21340667
Publisher site
See Article on Publisher Site

Abstract

Gastric Cancer (2011) 14:50–55 DOI 10.1007/s10120-011-0007-7 O R I G IN AL ARTI CL E Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis • • Francesco Montagnani Gina Turrisi • • Claudio Marinozzi Camillo Aliberti Giammaria Fiorentini Received: 10 August 2010 / Accepted: 26 September 2010 / Published online: 23 February 2011 The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2011 Abstract thromboembolic events (OR = 0.42, p \ 0.01), but it was Background Cisplatin has been largely used in the treat- also associated with increased neurotoxicity (OR = 6.91, ment of advanced, unresectable gastric cancer, mainly in p \ 0.01). combinations with fluoropyrimidines and anthracyclines. Conclusions Our results support the existence of a small Oxaliplatin has been shown to be at least as effective as but significant survival benefit of oxaliplatin over cisplatin. cisplatin for this disease, but with less toxicity and a better Oxaliplatin is associated with less toxicity and better tol- tolerability profile, especially for older patients. We per- erability, especially in older patients and when used in two- formed a systematic review of the literature to address and drug, bi-weekly regimens. quantify

Journal

Gastric CancerSpringer Journals

Published: Feb 23, 2011

There are no references for this article.